Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 417-422

  Bosco, Raffaella ^a   Rabusin, Marco ^b   Voltan, Rebecca ^a   Celeghini, Claudio ^c   Corallini, Federica ^a   Capitani, Silvano ^a   Secchiero, Paola ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Dasatinib; Leukemic cells; p53

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; SYNAPTOPHYSIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; G1 PHASE CELL CYCLE CHECKPOINTS; GRANULOCYTE PRECURSOR CELLS; HUMANS; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STAT3 TRANSCRIPTION FACTOR; THIAZOLES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856551239     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9564-6     Document Type: Article

References (16)

1. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med 354:2531-2541 (Pubitemid 43882349)
2. Amrein L, Hernandez TA, Ferrario C et al (2008) Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 143:698-706
3. Veldurthy A, Patz M, Hagist S et al (2008) The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 112:1443-1452
4. Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395-403 (Pubitemid 46780067)
5. Secchiero P, Zerbinati C, Melloni E et al (2007) The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia 9:853-861 (Pubitemid 47623425)
6. Tavolaro S, Chiaretti S, Messina M et al (2010) Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leuk Res 34:733-741
7. Zenz T, Kröber A, Sherer K et al (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329
8. Zauli G, Re MC, Furlini G, Giovannini M, La Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417-421
9. Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974 (Pubitemid 39094803)
10. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135 (Pubitemid 36753853)
11. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S (1996) Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 271:22961-22964 (Pubitemid 26314724)
12. Demetri GD, Lo Russo P, MacPherson IRJ (2009) Phase I doseescalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232-6240
13. Sainz-Perez A, Gary-Gouy H, Gaudin F et al (2008) IL-24 induces apoptosis of chronic lymphocytic leukemia B cellsengaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. J Immunol 181: 6051-6060
14. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD (2009) Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 15:1250-1258
15. Mirandola P, Ponti C, Gobbi G et al (2004) Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAILmediated cytotoxicity. Blood 104:2418-2424 (Pubitemid 39331842)
16. Cheng JC, Kinjo K, Judelson DR et al (2008) CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 111:1182-1192 (Pubitemid 351213399)